Quick question for the group — efinopegdutide mash data merck's gcg/glp-1 approach.

I searched before posting (promise!) but the threads I found were from 2024 and things seem to have changed since then.

My situation: I'm switching medications and this came up during my last appointment. My nurse mentioned it but did not go into detail.

Would love to hear from people who've actually dealt with this. What worked? What didn't? What do you wish someone had told you?

Thanks everyone — this forum has been invaluable for me.

TrialNerd_Beth's experience with Efinopegdutide MASH data resonates deeply with mine. I went through almost the identical process — starting dose, titration timeline, side effects, everything.

The main difference: I started 3 months later. But the overall trajectory has been remarkably similar. Down 34 lbs in 9 months.

One thing I would add that TrialNerd_Beth did not mention: the mental health improvements were just as significant.

Thanks for sharing this, TrialNerd_Beth. A few questions about your Efinopegdutide MASH experience:

1. What dose did you start at?
2. How long before you noticed side effects improving?
3. Did your provider have any specific recommendations about Efinopegdutide?

I am in a similar boat and trying to learn from others' experiences before my next appointment.

OP here — wow, did not expect this much response! Thank you all for the thoughtful replies on Efinopegdutide MASH data .

To answer jim_asheville: I get my labs done through Quest every 3 months.

Quick update: my latest labs came back even better. Thanks again for the evidence-based discussion — this is exactly why I posted in a science-based community. 🙏

Relevant to Efinopegdutide MASH data — here is my latest bloodwork comparison:

Key improvements: A1C 7.2% → 5.3%, triglycerides 247 → 117 mg/dL, hsCRP 6.0 → 1.1 mg/L. All on tirzepatide for 15 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.